FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149773975> ?p ?o ?g. }

• W2149773975 abstract "Penile cancer (PC) is a rare tumor, and therapeutic options are limited for this disease, with an overall 5-year overall survival around 65-70%. Adjuvant therapy is not recommended for patients with N0-1 disease, despite up to 60% of these patients will die within 5 years from diagnosis.Medical records of all patients who underwent radical surgery at University Federico II of Naples and at National Tumor Institute Pascale of Naples for early squamous cell carcinoma of the penis from January, 2000 to December, 2011 were retrieved. Paraffin wax embedded tissue specimens were retrieved from the pathology archives of the participating Institutions for all patients. Expression of p-EGFR, EGFR and positivity to HPV were evaluated along with other histological variables of interest. Demographic data of eligible patients were retrieved along with clinical characteristics such as type of surgical operation, time of follow up, time of recurrence, overall survival. A multivariable model was constructed using a forward stepwise selection procedure.Thirty eligible patients were identified. All patients were positive for EGFR by immunohistochemistry, while 13 and 16 were respectively positive for nuclear and cytosolic p-EGFR. No EGFR amplification was detected by FISH. Eight patients were positive for high-risk HPV by ISH. On univariable analysis, corpora cavernosa infiltration (OR 7.8; 95% CI=0,8 to 75,6; P=0,039) and positivity for cytosolic p-EGFR (OR 7.6; 95% CI =1.49 to 50; P = 0.009) were predictive for recurrence, while only positivity for cytosolic p-EGFR (HR =9.0; 95% CI 1.0-100; P=0,0116) was prognostic for poor survival.It is of primary importance to identify patients with N0-1 disease who are at increased risk of recurrence, as they do not normally receive any adjuvant therapy. Expression of p-EGFR was found in this series to be strongly related to increase risk of recurrence and shorter overall survival. This finding is consistent with the role of p-EGFR in other solid malignancies. Integration of p-EGFR with classic prognostic factors and other histology markers should be pursued to establish optimal adjuvant therapy for N0-1 PC patients." @default.
• W2149773975 created "2016-06-24" @default.
• W2149773975 creator A5012423170 @default.
• W2149773975 creator A5013035382 @default.
• W2149773975 creator A5014614796 @default.
• W2149773975 creator A5022468686 @default.
• W2149773975 creator A5023150524 @default.
• W2149773975 creator A5024587083 @default.
• W2149773975 creator A5027115920 @default.
• W2149773975 creator A5029398339 @default.
• W2149773975 creator A5050645858 @default.
• W2149773975 creator A5052069729 @default.
• W2149773975 creator A5055464636 @default.
• W2149773975 creator A5056241456 @default.
• W2149773975 creator A5062560884 @default.
• W2149773975 creator A5066976468 @default.
• W2149773975 creator A5067979730 @default.
• W2149773975 creator A5068374820 @default.
• W2149773975 creator A5078562748 @default.
• W2149773975 date "2013-07-02" @default.
• W2149773975 modified "2023-10-08" @default.
• W2149773975 title "Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study" @default.
• W2149773975 cites W1220249624 @default.
• W2149773975 cites W1578557984 @default.
• W2149773975 cites W1965441318 @default.
• W2149773975 cites W1973333007 @default.
• W2149773975 cites W1974997937 @default.
• W2149773975 cites W2006274713 @default.
• W2149773975 cites W2009883570 @default.
• W2149773975 cites W2010261892 @default.
• W2149773975 cites W2031981401 @default.
• W2149773975 cites W2044574682 @default.
• W2149773975 cites W2064739837 @default.
• W2149773975 cites W2078498661 @default.
• W2149773975 cites W2108972169 @default.
• W2149773975 cites W2111870880 @default.
• W2149773975 cites W2114161561 @default.
• W2149773975 cites W2117730523 @default.
• W2149773975 cites W2130070174 @default.
• W2149773975 cites W2146950088 @default.
• W2149773975 doi "https://doi.org/10.1186/1479-5876-11-161" @default.
• W2149773975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3717121" @default.
• W2149773975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23819610" @default.
• W2149773975 hasPublicationYear "2013" @default.
• W2149773975 type Work @default.
• W2149773975 sameAs 2149773975 @default.
• W2149773975 citedByCount "37" @default.
• W2149773975 countsByYear W21497739752013 @default.
• W2149773975 countsByYear W21497739752014 @default.
• W2149773975 countsByYear W21497739752015 @default.
• W2149773975 countsByYear W21497739752016 @default.
• W2149773975 countsByYear W21497739752017 @default.
• W2149773975 countsByYear W21497739752018 @default.
• W2149773975 countsByYear W21497739752019 @default.
• W2149773975 countsByYear W21497739752020 @default.
• W2149773975 countsByYear W21497739752021 @default.
• W2149773975 countsByYear W21497739752022 @default.
• W2149773975 countsByYear W21497739752023 @default.
• W2149773975 crossrefType "journal-article" @default.
• W2149773975 hasAuthorship W2149773975A5012423170 @default.
• W2149773975 hasAuthorship W2149773975A5013035382 @default.
• W2149773975 hasAuthorship W2149773975A5014614796 @default.
• W2149773975 hasAuthorship W2149773975A5022468686 @default.
• W2149773975 hasAuthorship W2149773975A5023150524 @default.
• W2149773975 hasAuthorship W2149773975A5024587083 @default.
• W2149773975 hasAuthorship W2149773975A5027115920 @default.
• W2149773975 hasAuthorship W2149773975A5029398339 @default.
• W2149773975 hasAuthorship W2149773975A5050645858 @default.
• W2149773975 hasAuthorship W2149773975A5052069729 @default.
• W2149773975 hasAuthorship W2149773975A5055464636 @default.
• W2149773975 hasAuthorship W2149773975A5056241456 @default.
• W2149773975 hasAuthorship W2149773975A5062560884 @default.
• W2149773975 hasAuthorship W2149773975A5066976468 @default.
• W2149773975 hasAuthorship W2149773975A5067979730 @default.
• W2149773975 hasAuthorship W2149773975A5068374820 @default.
• W2149773975 hasAuthorship W2149773975A5078562748 @default.
• W2149773975 hasBestOaLocation W21497739751 @default.
• W2149773975 hasConcept C121608353 @default.
• W2149773975 hasConcept C126322002 @default.
• W2149773975 hasConcept C143998085 @default.
• W2149773975 hasConcept C146357865 @default.
• W2149773975 hasConcept C151730666 @default.
• W2149773975 hasConcept C204232928 @default.
• W2149773975 hasConcept C2777180808 @default.
• W2149773975 hasConcept C2777982462 @default.
• W2149773975 hasConcept C71924100 @default.
• W2149773975 hasConcept C86803240 @default.
• W2149773975 hasConceptScore W2149773975C121608353 @default.
• W2149773975 hasConceptScore W2149773975C126322002 @default.
• W2149773975 hasConceptScore W2149773975C143998085 @default.
• W2149773975 hasConceptScore W2149773975C146357865 @default.
• W2149773975 hasConceptScore W2149773975C151730666 @default.
• W2149773975 hasConceptScore W2149773975C204232928 @default.
• W2149773975 hasConceptScore W2149773975C2777180808 @default.
• W2149773975 hasConceptScore W2149773975C2777982462 @default.
• W2149773975 hasConceptScore W2149773975C71924100 @default.
• W2149773975 hasConceptScore W2149773975C86803240 @default.
• W2149773975 hasIssue "1" @default.
• W2149773975 hasLocation W21497739751 @default.
• W2149773975 hasLocation W21497739752 @default.

• next